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INTRODUCTION: 
Cancer is a group of diseases characterized by 
uncontrolled growth and spread of abnormal cells. Cancer 
is caused by both external factors (tobacco, infectious 
organisms, chemicals, and radiation) and internal factors 
(inherited mutations, hormones, immune conditions, and 
mutations that occur from metabolism). Ten or more years 
often pass between exposure to external factors and 
detectable cancer. Cancer is treated with surgery, radiation, 
chemotherapy, hormone therapy, biological therapy, and 
targeted therapy. The American Cancer Society estimates 
that in 2012 about 173,200 cancer deaths will be caused by 
tobacco use. Many of the more than 2 million skin cancers 
that are diagnosed annually. Cancer researchers use the 
word ―risk‖ in different ways, most commonly expressing 
risk as lifetime risk or relat ive risk
1
. 
The National Cancer Institute estimates about 1,638,910 
new cancer cases are expected to be diagnosed in 2012. In  
2012, about 577,190 Americans are expected to die of 
cancer, more than 1,500 people a day. Cancer is the second 
most common cause of death in the US. By 2030, the 
global burden is expected to grow to 21.4 million new 
cancer cases and 13.2 million cancer deaths simply due to 
the growth and aging of the population, as well as 
reductions in childhood mortality and deaths from 
infectious diseases in developing countries
2
. 
Table 1: Cancer facts and figures according to National cancer Institute (NCI)  
                              Es timated New Cancer Cases and Deaths by Sex, US, 2012 
                                                            Estimated New Cases            Estimated Deaths 
 Both Sexes Male Female  Both Sexes Male Female  
Breast 229,060 2,190 226,870 39,920 410 39,510 
Prostate  241,740 241,740       - 28,170 28,170      - 
Lung & bronchus 226,160 116,470 109,690 160,340 87,750 72,590 
Colon  103,170 49,920 53,250 51,690 26,470 25,220 
Ovary 22,280       - 22,280 15,500       - 15,500 
Liver & intrahepatic bile duct 28,720 21,370 7,350 20,550 13,980 6,570 
Small intestine 8,070 4,380 3,690 1,150 610 540 
Brain & other nervous system 22,910 12,630 10,280 13,700 7,720 5,980 
Skin (exclud ing basal & squamous) 81,240 46,890 34,350 12,190 8,210 3,980 
Melanoma-skin  76,250 44,250 32,000 9,180 6,060 3,120 
Pancreas 43,920 22,090 21,830 37,390 18,850 18,540 
Urinary bladder 73,510 55,600 17,910 14,880 10,510 4,370 
Kidney & renal pelvis  64,770 40,250 24,520 13,570 8,650 4,920 
Genital system 340,650 251,900 88,750 58,360 28,840 29,520 
Lymphoma 79,190 43,120 36,070 20,130 10,990 9,140 
Myeloma 21,700 12,190 9,510 10,710 6,020 4,690 
 
ABSTRACT:  
Cancer is major health burden in developed countries as well as developing countries around the globe. Breast cancer, lung 
cancer, prostate cancer and colon cancer are responsible for  more than 50 percent of total deaths due to cancer . 
Chemotherapy is most popular and convenient form of treatment against almost all types of cancer. Products of natural 
origin are employed in chemotherapy for long time in the form of chemopreventive, chemosensitizing and 
chemotherapeutic agents. Combination drugs chemotherapy is considered to be more effective and safer way of treatment. 
This short review is an attempt to cover the combination of drugs from plant origin that are effective in most common 
cancers and their clinical status. 
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The primary modalit ies of cancer treatment are surgery, 
chemotherapy, and radiotherapy; these may be used alone 
or in combination. Surgical treatment
3,4
 depends on the 
stage of cancer, the organ affected and the patient 
condition. In surgically treated patients, pain relief can  
often be achieved and long term neurological stabilizat ion 
tends to persist more often that it does with conservatively 
treated patients. Surgical intervention may be appropriate 
for patients with advanced disease for avoiding urgent life- 
threatening symptoms or serious functional disorders that 
annoys patients daily life, but surgical treatment for elderly  
cancer patients should be carefully considered after 
weighing the risk of post operative mortality, morb idity, 
functional deterioration due to the surgery and speculated 
life surgery. Common surgical techniques are Laser 
surgery
5
, Cryosurgery
6
, Electrosurgery, Mohs surgery, 
Laparoscopic surgery, and Thorascopic surgery. Most 
often an adjuvant chemotherapy along with the surgical 
treatment of cancer is recommended. Surgical p rocedures 
for treatment of cancer is limited by Bleeding, Damage to 
internal organs and blood vessels, Reactions to drugs used 
(anesthesia) or other medicines, Problems with other 
organs, such as the lungs, heart, or kidneys, Infection at the 
site of the wound is another possible problem etc
7,8
.  
Radiat ion therapy is used to kill the cancer cells . It can 
also affect normal cells near the tumor. Rad iation is a local 
treatment. Two types of radiation therapy are being used: 
External beam radiation therapy and internal radiation 
therapy. Radiotherapy in particular is often used for pain 
relief without curative intent
9-11
. 
Fatigue (feeling very tired), Skin changes, Loss of appetite, 
hair loss, Nausea, vomiting, diarrhea, not wanting to eat, or 
trouble swallowing, new rash, new bruises, or bleeding, 
Weight loss can be  common side effects of rad iotherapy. 
Chemotherapy is a kind of treatment that uses drugs to 
attack cancer cells. Chemo may be used to: Keep the 
cancer from spreading, Slow the cancer’s growth, Kill 
cancer cells that may have spread to other parts of the 
body, Relieve symptoms such as pain or blockages caused 
by cancer, Cure cancer. At present more than 50 anticancer 
drugs have been discovered. They are used in several 
ways: Monotherapy or only one drug, combined modality 
or chemotherapy along with other treatment such as 
surgery and radiotherapy, Combination chemotherapy or a 
group of drugs which work together. Major  Side effects of 
chemotherapy are Nausea and vomit ing, Hair loss, Bone 
marrow changes(Red blood cells, White blood cells, 
Platelets), Mouth and skin changes, Fertility problems , 
Memory changes, Emot ional changes
12,13
. 
NATURAL DRUGS US ED IN CANCER THERAPY:   
Drugs obtained from natural orig in contribute a major part  
in cancer treatment. An analysis of the number of 
chemotherapeutic agents and their sources indicates that 
over 60% of approved drugs are derived from natural 
compounds
14
. Some recent developments in cancer 
chemotherapy from natural origin are summarized in table  
II. 
Table2: Summary of Drugs of Plant origin in different types of cancer 
Drugs Type of cancer Mechanism of action Ref 
Camptothecin Metastatic colon and rectal cancer  topoisomerase I 15-23 
combretastatin A-4 Lung carcinoma and breast cancer  tubulin binding 24-29 
Epipodophyllotoxin small cell lung cancer, testicular 
carcinoma, lymphoma 
topoisomerase I and II  30 
Homoharrington Lung carcinoma, colon 
adinocarcinoma 
Protein synthesis inhibition 31-34 
Ingenol Skin cancer protein kinase C activation 35-39 
Daidzein Breast and prostate cancer NADH oxidase (tNOX) inhibition 40-43 
Paclitaxel Breast, ovarian, lung, bladder, 
prostate, melanoma 
tubulin stabilization 44-52 
Protopanaxadiol stomach, lung, liver, pancreas, 
ovaries, & colon  
caspase 3, 8 and 9 stimulant 53-55 
Triptolide Prostate cancer T-cell proliferation suppression, IL-2 expression and 
NFj-B activation 
56-62 
Vinblastine Hodgkin's lymphoma, non-small cell 
lung cancer, breast, head and neck, 
& testicular cancer 
tubulin binding 63,64 
Quercetin/Resveratrol Colorectal cancer  induction of expression of caspase 3/8, causing DNA 
fragmentation, and arresting cells in G1 phase of the 
cell cycle 
65 
7,12-dimethylbenz(a) 
anthracene 
Breast cancer  induced mammary carcinogenesis, and suppressed 
proliferation and lipogenesis in MCF-7 breast cancers 
66,67 
docosahexaenoic acid 
(DHA) 
Prostate cancer increased lipid peroxidation and enhanced efficacy of 
anticancer drugs  
68 
glycyrrhizic acid and 
oleanolic acid 
Skin cancer, Colon cancer and 
breast 
Activate proapoptotic signaling cascades and 
suppression or nuclear translocation of various 
transcription factors including nuclear factor kappa B 
(NF-κB). 
69 
Berberine hydrochloride Lung cancer Bind specifically to oligonucleotides and to stabilize 
DNA triplexes or G-quadruplexes via telomerase and 
topoisomerase inhibition.  
70 
Curcumin advanced pancreatic cancer  suppresses nuclear factor-nB (NF-nB) activation 71 
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Resveratrol 
(Pterostilbene) 
Breast cancer Inhibit both apoptosis and cell cycle arrest 72 
ginsenoside 25-OH-
PPD 
prostate cancer reduced expression of MDM2, E2F1, Bcl2, cdk2/4/6, 
and cyclin D1, which correlated with the cell cycle 
arrest in G1 and the decrease in proliferation 
73 
Thymoquinone colon, prostate, pancreatic and lung 
cancer 
anti-proliferation, apoptosis induction, cell cycle 
arrest and anti-metastasis/anti-angiogenesis  
74 
Docetaxel Breast cancer Bind to the β-tubulin subunits of microtubules, which 
prevents their depolymerization and blocks cell 
growth in the G2-M phase 
75 
 
COMBINATION CANCER THERAPY: 
Chemotherapy drugs are most effective when given in  
combination (combination chemotherapy). The rationale 
for combination chemotherapy is to use drugs that work 
by different mechanisms of action, thereby decreasing the 
likelihood that resistant cancer cells will develop. When 
drugs with different effects are combined, each drug can 
be used at its optimal dose, without intolerable side 
effects.  
Combinations used in breast Cancer: 
Breast cancer (malignant breast neoplasm) is a type of 
cancer originating from breast tissue, most commonly  
from the inner lin ing of milk ducts or the lobules that 
supply the ducts with milk
76
. Worldwide, breast cancer 
comprises 22.9% of all cancers (excluding non-melanoma 
skin cancers) in women
77
. In 2008, breast cancer caused 
458,503 deaths worldwide (13.7% of cancer deaths in 
women)
77
. Breast cancer is more than 100 t imes more 
common in women than breast cancer in men, although 
males tend to have poorer outcomes due to delays in 
diagnosis
77-79
. An estimated 226,870 new cases of 
invasive breast cancer are expected to occur among 
women in the US during 2012; about 2,190 new cases are 
expected in men. 
Nabholtz JM suggested that the taxanes and 
anthracyclines have emerged as the most active agents for 
treating women with advanced breast cancer
80,81
. Phase II 
trials of the docetaxel combinations with either 
doxorubicin or epirubicin showed high activity, with 
acceptable tolerability in patients with metastatic breast 
cancer. Consequently, three randomized trials have 
compared docetaxel-anthracycline-based regimens with 
standard anthracycline-based polychemotherapies as first-
line therapy for women with advanced breast cancer. 
Therefore, docetaxel-anthracycline combinations 
represent a validated option in first-line treatment for 
women with advanced breast cancer, and are further 
evaluated as adjuvant treatment for early stage breast 
cancer. Joensuu H et al showed that adjuvant treatment 
with docetaxel, as compared with vinorelbine, improves 
recurrence-free survival in women with early breast 
cancer, when docetaxel compared with vinorelb ine for the 
adjuvant treatment of early breast cancer
82-88
, a short 
course of trastuzumab admin istered concomitantly with 
docetaxel or vinorelbine is effect ive in women with breast 
cancer who have an amplified HER2/neu gene. 
Pretreatment with dexamethasone increases antitumor 
activity of carboplatin and gemcitabine
89
. To our 
knowledge, this is the first report that DEX significantly  
enhances the antitumor activity of carboplatin and 
gemcitabine and increases their accumulat ion in tumors. 
These results provide a basis for further evaluation of 
DEX as a chemosensitizer in patients. Eichhorn PJ et al 
identified the tumor suppressor PTEN as a modulator of 
lapatinib sensitivity in vitro and in vivo
90
. Their data 
show that deregulation of the PI3K pathway, either 
through loss-of-function mutations in PTEN or dominant 
activating mutations in PIK3CA, leads to lapatinib 
resistance, which can be effectively reversed by NVP-
BEZ235. A recent phase III trial demonstrated that the 
combination of capecitabine (Xeloda) and docetaxel 
(Taxotere) significantly improved objective tumor 
response rate, time to disease progression, and overall 
survival compared with single-agent docetaxel in  
anthracycline-pretreated patients with advanced breast 
cancer
91
. Green tea polyphenol EGCG synergistically  
sensitized breast cancer cells to paclitaxel in v itro and in  
vivo
92
. EGCG in combination with paclitaxel 
significantly induced 4T1 cells apoptosis compared with 
each single treatment. EGCG may be used as a sensitizer 
to enhance the cytotoxicity of paclitaxel.  
Combinations used in Prostate Cancer: 
Prostate cancer is the most common human visceral 
malignancy and the third most common cause of cancer-
related deaths among men in the Westernized world
93
. 
Autopsy studies show that men in the fourth decade of 
life have a one-third risk of harboring small carcinomas
94
. 
Death rates from prostate cancer vary across the globe, 
with Westernized nations having the highest risk of 
incidence and death and Asian nations having the 
lowest
95
. 
Many tumors constitutively express high levels of the 
inducible form of p roinflammatory enzyme, 
cyclooxygenase-2 (COX-2)
96
. Combination of Celecoxib  
and docetaxel inhib ited  COX-2 activity and associated 
alteration in cell death signaling, a potential clin ical use 
of combined dosing of COX-2 inhibitors and cytotoxic 
drugs at lower, nontoxic dose than currently used to treat 
advanced prostate cancer. McCubrey JA et al isolated cell 
with the cancer init iating cell (CIC) phenotype from PC3 
cells
97
. Low doses of genistein can increase the sensitivity 
of prostate CICs to drugs such as docetaxel and 
cyclopamine, two drugs either used or under 
consideration for prostate cancer therapy. The polyamine 
analog PG11047 potentiates the antitumor activity of 
cisplatin and bevacizumab in preclin ical models of 
prostate cancer 
98
. The objective of the present study was 
to assess the antitumor effects of PG11047 alone and in 
combination with approved anti-cancer agents. Another 
study showed that demonstrate the potential anticancer 
efficacy of genistein-topotecan combination in LNCaP 
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prostate cancer cells and the mechanism of the 
combination treatment
99
. Treatments involving genistein-
topotecan combination may prove to be an attractive 
alternative phytotherapy or adjuvant therapy for prostate 
cancer. An exploratory analysis of phase III trial 
participants found a substantial survival benefit to 
receiving docetaxel some months after sipuleucel-T
100
. 
Sipuleucel-T is an active immunotherapy that triggers T-
cell responses against prostate cancer. This trial 
highlights major unresolved questions concerning the 
optimum choice, dosing, and timing of chemotherapy 
relative to active immunotherapy. Stearns ME and Wang 
M have examined whether epigallocatechin-3-gallate 
(EGCG), and extract of green tea, in combination with 
taxane (i.e., paclitaxel and docetaxel), exe rts a synergistic 
activity in blocking human prostate PC-3ML tumor cell 
growth in vitro and in vivo
101
.  
The overall chance of death from prostate cancer, even 
among Westernized nations that have not historically  
treated the disease for cure, is 3.5% to 4%
102
. Given the 
large d iscordance between histologic incidence and death, 
there is great potential for overdetection and 
overtreatment. This is even more relevant as treatment-
related morb idit ies associated with prostate cancer 
treatment can impact urinary function, sexual function, 
and quality of life
103
. Disease prevention thus offers an 
attractive paradigm for addressing this important public 
health problem. 
Combinations used in Colon Cancer: 
An estimated 103,170 cases of colon and 40,290 cases of 
rectal cancer are expected to occur in 2012. Colon cancer, 
the fourth most common cancer in the world, is one of the 
leading causes of cancer death in both men and women in 
Western countries, including the USA
104,105
. An expert 
panel assembled by the American Ins titute for Cancer 
Research/World Cancer Research Foundation came to a 
scientific consensus that there is evidence for a 
correlation between a high intake of saturated fats (and/or 
animal fat) and colon cancer risk
106
. 
Schröder CP, Maurer HR demonstrated in vitro, that 
pretreatment of human LS 174T co lon cancer cells with 
nontoxic concentrations of tributyrin augments the 
sensitivity to spontaneous NK cell activ ity two-fold
107
. 
However, when NK cells have been activated with an 
optimized combination of IL-2 and IL-12, the 
immunocytotoxicity increases up to five-fold (from 14% 
to 70%), versus a 3.8-fo ld increase against untreated 
cancer cells. These data suggested a synergistic link 
between induction of tumor cell differentiat ion and 
immunological defense mechanisms that may provide a 
rational basis for the improvement of clinical protocols, 
especially for colon cancer. In vitro
108
, viable cell growth 
was determined by trypan blue exclusion assay and cell 
death was investigated by flow cytometry. ALA (50 
µg/ml) and HESW (E1, EFD = 0.22 mJ/mm², 1000 shots 
or E2, EFD = 0.88 mJ/mm², 500 shots) showed a 
significant reduction of cancer cell proliferation at day 3 
compared to cells exposed to ALA (p < 0.01) or HESW  
(p < 0.001) alone. In v ivo, apoptosis detection was carried  
out by TUNEL assay, the pro-apoptotic gene Bad and 
Bcl-2 mRNA expression was evaluated by quantitative 
SYBR Green real time RT-PCR and cleavage of poly 
(ADP-ribose)-polymerase (PARP) was investigated by 
Western Blotting. The interaction between HESW and 
ALA is then effective in inducing apoptosis on a 
syngeneic colon cancer model
108
. Antitumor activities of 
carboplatin and gemcitabine with or without DEX 
pretreatment were determined in six murine-human 
cancer xenograft models, including cancers of colon 
(LS174T)
89
. Although DEX alone showed minimal 
antitumor activity, DEX pretreatment significantly  
increased the efficacy of carboplatin, gemcitabine, or a 
combination of both drugs by 2-4-fold in all xenograft  
models tested and increased their accumulation in tumors. 
Majumdar AP et al described that the combination of 
curcumin and resveratrol was found to be more effective 
in inhibit ing growth of p53-positive (wt) and p53-
negative colon cancer HCT-116 cells in v itro and in vivo 
in SCID xenografts of colon cancer HCT-116 (wt) cells 
than either agent alone
110
. In vitro studies have further 
demonstrated that the combinatorial treatment caused a 
greater inhibition of constitutive activation of EGFR and 
its family members as well as IGF-1R. Their current data 
suggest that the combination of curcumin and resveratrol 
could be an effective preventive/therapeutic strategy for 
colon cancer. In other review Felth J et al described that 
some cardiac glycosides (digitoxin, digoxin, 
Convallatoxin) have been reported to exhibit cytotoxic 
activity against several different cancer types like 
colorectal cancer etc
111
. The combination of oxaliplatin  
and oxaliplatin exh ibited synergism including the 
otherwise highly drug-resistant HT29 cell line. These 
findings demonstrate that such substances may exh ibit  
significant activity against colorectal cancer cell lines. 
Combinations used in lung cancer: 
Lung cancer is the leading cause of cancer-related death 
in the world and can be broadly classified into small cell 
lung cancer (SCLC) and non–small-cell lung cancer 
(NSCLC)
112
. NSCLC accounts for approximately 85% of 
all lung cancers
113
, and unlike SCLC, NSCLC is less 
sensitive to chemotherapeutic agents.  
Natural compounds in combination with chemotherapy 
agents enhance anticancer activities of drugs and reduce 
their toxicity. Milczarek M et al determined an effect of 
isothiocyanates and 5-fluorouracil used alone or in 
combination (in sequential or co-admin istrative 
treatments) on normal cell lines -V79
114
. There was 
observed an antagonistic effect which was mainly  
dependent on the cell cycle distribution and their 
combination increased the cell number in the S phase. 
Another combination therapy using paclitaxel (PTX) as 
chemotherapeutic molecule and theophylline (TH) as 
differentiative agent in the prevention of metastasis in 
B16-F10 melanoma-bearing C57BL6/N mice. In vitro  
proliferation studies demonstrated that TH enhanced the 
antiproliferative effect of PTX. This study demonstrated 
that the simultaneous treatment of mice with TH and a 
low dose of PTX produced a similar anti-invasive effect 
than that caused by highly toxic PTX concentration
115
. 
Antitumor activities of carboplatin and gemcitabine with 
DEX pretreatment were determined in human cancer 
xenograft models, including lung (A549 and H1299) 
cancer
89
. DEX pret reatment significantly increased tumor 
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carboplatin levels, including 200% increase in area under 
the curve, 100% increase in maximum concentration, and 
160% decrease in clearance. DEX pretreatment similarly  
increased gemcitabine uptake in tumors. In other review 
PG11047 is a polyamine analog currently in Phase I trials 
for advanced cancer in combination with a number of 
approved anti-cancer agents
98
. The antitumor efficacy of 
PG11047 as a single agent, and in combination with 
cisplatin and bevacizumab, was tested in models of lung 
(A549) cancer and the result that PG11047 potentiated 
the antitumor effect of cisplatin. Green tea is now 
recognized as the most effective cancer preventive 
beverage
116
. The synergistic enhancement of apoptosis 
and GADD153 gene expression in human non-small cell 
lung cancer cells by the combination of EGCG and 
celecoxib were mediated through the activation of the 
MAPK signaling pathway. This article reviews the 
synergistic enhancement of apoptosis, gene expression, 
and anticancer effects using various combinations of 
EGCG and anticancer drugs. Saha A et al studied the 
enhancing effects of EC on inductions of growth 
inhibit ion and apoptosis in human lung cancer cell lines 
PC-9 and A549 with curcumin. The combination 
similarly increased both apoptosis and expression of 
GADD153 and GADD45 genes, associated with their 
enhanced protein production
117
. This report is the first 
report on the enhancing effects of EC on curcumin, and 
the data suggest that EC plays a significant role in the 
enhancement of the cancer-preventive activity of 
curcumin in the diet. 
CONCLUS ION:  
Numerous experimental, clinical, and epidemiologic 
studies indicate that combination of drugs particularly  
natural drug combination show promise as anticancer 
drugs chemotherapy. The clinical application of these 
combination drugs is still limited by the lack of 
randomized evidence of their efficacy and safety. The 
combination therapy is defin itely a promising area in  
chemotherapy to reduce the dose of anticancer drugs 
henceforth the adverse effects as well but more clinical 
studies are required. 
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Table3: Summary of combinations of drugs of herbal orig in in d ifferent types of cancer 
Drugs Mechanism of Action 
Clinical 
Status 
Type of Cancer Ref 
Isothiocyanates and 5-
fluorouracil 
Increased the cell number in the S phase 
 
Lung cancer 114 
paclitaxel (PTX) and 
theophylline (TH) 
TH enhanced the antiproliferative effect of PTX 
 
Lung metastasis 115 
Docetaxel and doxorubicin Showed high activity, with acceptable 
tolerability 
II 
Metastatic breast cancer  80,81 
Trastuzumab and 
docetaxel/vinorelbine 
Specific for HER-2-overexpressing tumor cells  
II 
Breast cancer 82-88 
Glucocorticoid and irinotecan Decreased incidence and duration of diarrhea  Advanced colorectal cancer 118 
Celecoxib and docetaxel Inhibit COX-2 activity and associated alteration 
in cell death signaling 
 
Advanced prostate cancer  96 
Dexamethasone and  
carboplatin/ gemcitabine 
Enhanced the antitumor activity and increased 
their accumulation in tumors 
 
Colon, Lung, 
and Breast cancers  
89 
Budesonide and loperamide Decreased incidence and duration of diarrhea  
 
Advanced Colorectal 
cancer 
118 
Cisplatin and HemoHIM Enhanced the antitumor efficacy and decreased 
the tumor size and weight 
 
Melanoma 119 
genistein and cyclopamine BC cells are usually more rapidly proliferating 
than the CICs 
 
Prostate cancer 97 
Lapatinib and trastuzumab Inhibited growth of HER2þ tumors resistant to 
anti-HER2 therapy 
III 
Advanced and metastatic 
breast cancer 
90 
capecitabine (Xeloda) and 
docetaxel (Taxotere)  
Improved tumor response rate, time to disease 
progression, and overall survival 
III 
Advanced breast cancer  91 
PG11047 and cisplatin and 
bevacizumab 
 Inhibit polyamine biosynthetic enzymes, induce 
the polyamine catabolic enzymes 
spermidine/spermine N(1)-acetyltransferase 
(SSAT) and spermine oxidase (SMO) 
I 
Lung and Prostate cancer  98 
genistein-topotecan   Prostate cancer 99 
Sipuleucel-T and  docetaxel Triggers T-cell responses III Advanced prostate cancer  100 
EGCG and paclitaxel/ 
sulindac/ celecoxib/ 
doxorubicin 
Inhibits TNF-α-induced promoter activity of the 
chemokine IL-8 by an interference with the 
IκB/NFκB pathway/ activation of the MAPK 
signaling pathway/ inhibited P-glycoprotein (P-
gp) efflux pump activity/ blocking human 
prostate PC-3ML tumor cell growth in vitro and 
in vivo. 
 
Breast carcinoma / lung 
cancer/ liver cancer/ 
Prostate cancer 
92,101
, 
116,12
0, 
121 
Curcumin with (-)-epicatechin 
(EC) 
Increased both apoptosis and expression of 
GADD153 and GADD45 genes 
 
Lung cancer 117 
Gemcitabine and 
Guggulsterone 
 
Enhanced antitumor efficacy through apoptosis 
induction by suppressing Akt and nuclear factor 
κB activity 
 
Pancreatic Cancer 29 
Curcumin and resveratrol Inhibiting growth of p53-positive (wt) and p53-
negative colon cancer HCT-116 cells in vitro and 
in vivo in SCID xenografts of colon cancer 
HCT-116 (wt) cells 
 
Colorectal cancer 110 
Convallatoxin and oxaliplatin  Exhibited synergism including the otherwise 
highly drug-resistant HT29 cell line 
 
Colon cancer 111 
